Nephrocare Health Services has approved trading plans for two senior executives to sell their equity holdings, providing transparency on potential supply pressure in the coming months. The company intimated the Bombay Stock Exchange and the National Stock Exchange on August 5, 2026, regarding the pre-approved plans submitted by Group Chief Executive Officer Rohit Singh and CEO India and Nepal Business Sukaran Singh Saluja. These disclosures are mandatory under Regulation 5(5) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, ensuring that designated persons trade within predefined parameters to prevent insider trading concerns.

The trading plans were approved on August 5, 2026, following submission by the respective executives. The plans are irrevocable once approved, meaning the executives must execute the trades if market conditions permit, though they retain the right not to trade if unpublished price-sensitive information remains undisclosed. The price limits for these transactions were derived from the closing price on August 4, 2026, which stood at ₹713.15 on the National Stock Exchange of India Ltd. The minimum execution price is set at ₹700.00 per equity share, representing a buffer of up to 20% below the reference closing price.

Trading Plan Details

Both executives have scheduled their sales for the same five-day window in December 2026. The specific terms of the approved plans are outlined below:

Rohit Singh’s plan involves the sale of 30,000 equity shares, while Sukaran Singh Saluja intends to sell 60,000 equity shares. The total number of shares slated for sale under these plans is 90,000. The trading window is fixed between Monday, December 7, 2026, and Friday, December 11, 2026.

Regulatory Compliance and Conditions

The executives confirmed adherence to the cool-off period of 120 calendar days as prescribed under Regulation 5(2)(i) of the SEBI PIT Regulations. They also undertook not to trade for market abuse purposes. A critical condition of these plans is that execution will only occur if the stock price remains within the specified limit range; if the price falls below ₹700.00 or rises significantly above the upper bound implied by the derivation method, the trades may not be executed as planned. Furthermore, neither executive will implement the plan if any unpublished price-sensitive information held at the time of formulation has not become generally available by the commencement of the trading period.

What This Means for Investors

The disclosure of these trading plans allows investors to anticipate potential selling pressure from key insiders during the specified December window. While the sales are structured to comply with regulatory safeguards against insider trading, the volume of 90,000 shares represents a notable liquidity event. Investors should monitor the stock’s price action relative to the ₹700 floor during the December 7–11 period, as any deviation could signal changes in market sentiment or execution delays.

Nephrocare Health Services has scheduled its earnings conference call for Wednesday, August 12, 2026, at 10:00 AM IST to discuss its financial performance for the first quarter of fiscal year 2027 (Q1FY27). The event serves as a platform for investors and analysts to engage with the company's leadership regarding the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. This disclosure ensures transparency and provides stakeholders with direct access to management’s perspective on recent operational outcomes and strategic direction.

The announcement was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Nephrocare Health Services Limited, formerly known as Nephrocare Health Services Private Limited, filed the intimation with both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE). The company emphasized that discussions during the call will be based solely on publicly available information, with no intention to disclose unpublished price-sensitive information (UPSI).

Key Management Participants

The conference call will feature senior executives from NephroPlus, the brand under which the company operates as Asia's Largest Dialysis Network. The following officials are confirmed to participate in the discussion:

These leaders will address queries related to the company’s business strategy and future outlook post the declaration of its Q1FY27 financial results.

Call Logistics and Access Details

Investors can join the call via dial-in numbers provided for domestic and international participants. The event is organized in collaboration with IIFL, which has provided pre-registration links and contact details for further assistance. Below are the access details for the conference call:

For additional information, investors may contact Naman Bagrecha, Rahul Jeewani, Aman Goyal, or Vighnesh Indure at IIFL Capital Markets using the provided telephone numbers and email addresses. The full disclosure document is also available on the company’s official website at www.nephroplus.com .